EstechPharma Co Ltd banner
E

EstechPharma Co Ltd
KOSDAQ:041910

Watchlist Manager
EstechPharma Co Ltd
KOSDAQ:041910
Watchlist
Price: 7 870 KRW -8.59% Market Closed
Market Cap: ₩106.2B

Relative Value

The Relative Value of one EstechPharma Co Ltd stock under the Base Case scenario is 4 756.16 KRW. Compared to the current market price of 7 870 KRW, EstechPharma Co Ltd is Overvalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
4 756.16 KRW
Overvaluation 40%
Relative Value
Price
E
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
EstechPharma Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
EstechPharma Co Ltd
KOSDAQ:041910
104.5B KRW 1.8 14.8 24.4 47.6
US
Eli Lilly and Co
NYSE:LLY
866.1B USD 13.1 41.3 27.9 29.8
US
Johnson & Johnson
NYSE:JNJ
569.6B USD 6 21.1 14.7 18
CH
Roche Holding AG
SIX:ROG
243.3B CHF 4 18.9 11.2 12.6
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 4.9 28.3 15.7 22.2
US
Merck & Co Inc
NYSE:MRK
282.8B USD 4.3 15.4 9.6 11.7
CH
Novartis AG
SIX:NOVN
222.2B CHF 5.1 20.5 12.7 16.3
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.7 9
US
Pfizer Inc
NYSE:PFE
153.1B USD 2.4 19.7 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
115.4B USD 2.4 16.3 6.9 8.6
P/E Multiple
Earnings Growth PEG
KR
E
EstechPharma Co Ltd
KOSDAQ:041910
Average P/E: 20.7
14.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.3
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.1
7%
3
CH
Roche Holding AG
SIX:ROG
18.9
14%
1.3
UK
AstraZeneca PLC
LSE:AZN
28.3
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.4
14%
1.1
CH
Novartis AG
SIX:NOVN
20.5
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
19.7
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.3
16%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
E
EstechPharma Co Ltd
KOSDAQ:041910
Average EV/EBITDA: 46.7
24.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.9
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.7
2%
7.3
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
15.7
13%
1.2
US
Merck & Co Inc
NYSE:MRK
9.6
3%
3.2
CH
Novartis AG
SIX:NOVN
12.7
5%
2.5
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
1%
7.7
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.9
-10%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett